{"schema_version":"1.0","hypothesis_id":39978,"triple":{"drug":"Canagliflozin","drug_canonical":"canagliflozin","mediator":"AMPK","mediator_canonical":"AMPK","outcome":"epileptiform network activity","outcome_canonical":"epileptiform network activity"},"domain":{"domain":"cross_domain","source":"type_2_diabetes","target":"epilepsy"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1016/j.biopha.2023.114907","pmid":"37247463","year":2023,"roles":["drug_mediator"],"title":"Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway","journal":"Biomed Pharmacother","work_id":249846,"publication_date":"2023-05-26"},{"doi":"10.1002/1878-0261.13508","pmid":"37584455","year":2023,"roles":["drug_mediator"],"title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α","journal":"Mol Oncol","work_id":238977,"publication_date":"2023-08-19"},{"doi":"10.1161/jaha.122.028623","pmid":"36583437","year":2022,"roles":["drug_mediator"],"title":"Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia","journal":"J Am Heart Assoc","work_id":237759,"publication_date":"2022-12-30"},{"doi":"10.1093/brain/awac037","pmid":"35134125","year":2022,"roles":["mediator_outcome"],"title":"AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures","journal":"Brain","work_id":40553,"publication_date":"2022-02-01"},{"doi":"10.1186/s13098-019-0454-6","pmid":"31367234","year":2019,"roles":["drug_mediator"],"title":"Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice","journal":"Diabetol Metab Syndr","work_id":243375,"publication_date":"2019-07-22"},{"doi":"10.1186/s12967-019-1881-8","pmid":"30992077","year":2019,"roles":["drug_mediator"],"title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","journal":"J Transl Med","work_id":233569,"publication_date":"2019-04-16"},{"doi":"10.1038/s41598-018-23420-4","pmid":"29588466","year":2018,"roles":["drug_mediator"],"title":"Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","journal":"Sci Rep","work_id":232486,"publication_date":"2018-03-27"},{"doi":"10.1016/j.molmet.2016.08.014","pmid":"27689018","year":2016,"roles":["drug_mediator"],"title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","journal":"Mol Metab","work_id":232458,"publication_date":"2016-09-02"},{"doi":"10.2337/db16-0058","pmid":"27381369","year":2016,"roles":["drug_mediator"],"title":"The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels","journal":"Diabetes","work_id":232165,"publication_date":"2016-07-05"}],"source_paper_count":9,"extracted_claims":[{"side":"drug_mediator","object":"AMPK","context":"in vitro","subject":"canagliflozin","work_id":232165,"claim_id":164585,"polarity":"positive","predicate":"activates","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in mouse liver","subject":"canagliflozin","work_id":232165,"claim_id":164589,"polarity":"positive","predicate":"activates","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in prostate and lung cancer cells","subject":"Canagliflozin","work_id":232458,"claim_id":165304,"polarity":"positive","predicate":"activates","confidence":0.85,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in cultured human endothelial cells","subject":"canagliflozin","work_id":232486,"claim_id":165421,"polarity":"positive","predicate":"activates","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in rat myocardium","subject":"canagliflozin","work_id":233569,"claim_id":168294,"polarity":"positive","predicate":"activates","confidence":0.8,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in ischemic myocardium","subject":"Canagliflozin","work_id":237759,"claim_id":178540,"polarity":"positive","predicate":"activates","confidence":0.8,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in NSCLC cells","subject":"canagliflozin","work_id":238977,"claim_id":181223,"polarity":"positive","predicate":"activates","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in CRL1927 mesangial and THP-1 macrophage cell lines","subject":"canagliflozin","work_id":243375,"claim_id":191101,"polarity":"positive","predicate":"activates","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in endothelial cells treated with carfilzomib","subject":"canagliflozin","work_id":249846,"claim_id":205456,"polarity":"positive","predicate":"activates","confidence":0.7,"extraction_run_id":27},{"side":"mediator_outcome","object":"epileptiform network activity","context":"in thalamic brain slices","subject":"AMPK","work_id":40553,"claim_id":22912,"polarity":"positive","predicate":"increases","confidence":0.8,"extraction_run_id":14}],"extracted_claim_count":10,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[14,27]},"bridge":{"a_to_b_predicate":"activates","b_to_c_predicate":"increases","a_to_b_evidence_count":9,"b_to_c_evidence_count":1,"edge_support_log_ab":2.302585092994046,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.29957322735539915,"score":0.29957322735539915,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}